Product Type: Market Research Report
Published Date: July 2002
Published By: Drug & Market Development
Page Count: 200
Order Code: R294-0060
Print Copy: $2475
The price of this study has been reduced from $4,950 due to its age.
Up to 40% of molecules currently emerging from drug discovery are either insoluble or poorly soluble
A record number of biological products are under development, increasing the demand for improved formulations that address their specific challenges. These new drugs, including peptides, proteins, monoclonal antibodies and gene-based products, tend to be unstable in aqueous form and tend to be very sensitive to heat, pressure, and other environmental conditions.
DandMD's Overcoming Formulation Challenges examines current and emerging technologies that are essential to formulating insoluble small molecules. In addition, this Report focuses on the impact of new strategies employed by companies for creating stable biological drug formulations including new approaches that enable developers to produce biological drugs that are stable at room temperature.
Unique Benefits of This Report:
Understand the need for change by examining key factors in formulations and what options are, and will be, available to address new requirements
Make informed technical decisions by reading comparisons of new technologies that will impact formulations for both small molecule and biological drugs
Uncover issues affecting the supplier market including how excipient manufacturers are overcoming regulatory and financial constraints to create new products
Learn key issues driving formulations technologies as we breakdown the variables that must be addressed in formulating biological drugs along with the potential means of addressing the challenges presented by each variable
Focus on the commercial benefits by realizing how formulations and the products used in formulations will become product positioning tools and provide a competitive advantage for manufacturers
Keep your eye on how industry leaders are adapting with a thorough analysis of 30 companies and their formulations strategies moving forward.
 |
kavya says: | 2009-11-21 06:05:29 |
| worst case | ||
Comments: 1